NasdaqGM:XLRN

Stock Analysis Report

Executive Summary

Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases.

Snowflake

Fundamentals

Excellent balance sheet and slightly overvalued.

Share Price & News

How has Acceleron Pharma's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

1.5%

XLRN

2.0%

US Biotechs

1.0%

US Market


1 Year Return

-16.0%

XLRN

-5.5%

US Biotechs

8.0%

US Market

Return vs Industry: XLRN underperformed the US Biotechs industry which returned -5.5% over the past year.

Return vs Market: XLRN underperformed the US Market which returned 8% over the past year.


Shareholder returns

XLRNIndustryMarket
7 Day1.5%2.0%1.0%
30 Day-1.3%-2.2%-0.07%
90 Day0.1%-2.0%-1.0%
1 Year-16.0%-16.0%-4.6%-5.5%10.4%8.0%
3 Year53.9%53.9%15.4%11.4%46.2%36.7%
5 Year18.7%18.7%-3.1%-7.8%64.3%46.2%

Price Volatility Vs. Market

How volatile is Acceleron Pharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Acceleron Pharma undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: XLRN ($42.53) is trading below our estimate of fair value ($132.74)

Significantly Below Fair Value: XLRN is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: XLRN is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: XLRN is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate XLRN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: XLRN is overvalued based on its PB Ratio (4.5x) compared to the US Biotechs industry average (2.6x).


Next Steps

Future Growth

How is Acceleron Pharma forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?

45.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: XLRN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: XLRN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: XLRN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: XLRN's revenue (36.1% per year) is forecast to grow faster than the US market (7.2% per year).

High Growth Revenue: XLRN's revenue (36.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: XLRN is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Acceleron Pharma performed over the past 5 years?

-20.5%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: XLRN is unprofitable, and losses have increased over the past 5 years at a rate of -20.5% per year.

Accelerating Growth: Unable to compare XLRN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: XLRN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (83.4%).


Return on Equity

High ROE: XLRN has a negative Return on Equity (-23.93%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: XLRN is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: XLRN is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Acceleron Pharma's financial position?


Financial Position Analysis

Short Term Liabilities: XLRN's short term assets ($445.7M) exceeds its short term liabilities ($26.1M)

Long Term Liabilities: XLRN's short term assets (445.7M) exceeds its long term liabilities (24.9M)


Debt to Equity History and Analysis

Debt Level: XLRN is debt free.

Reducing Debt: XLRN had no debt 5 years ago.


Balance Sheet

Inventory Level: XLRN has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if XLRN's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: XLRN has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if XLRN has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Acceleron Pharma's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage2.3%forecastin3Years0%

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate XLRN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate XLRN's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if XLRN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if XLRN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of XLRN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Acceleron Pharma's salary, the management and board of directors tenure and is there insider trading?

5.9yrs

Average management tenure


CEO

Habib Dable (50yo)

2.8yrs

Tenure

US$4,333,647

Compensation

Mr. Habib J. Dable has been the Chief Executive Officer and President at Acceleron Pharma Inc. since joining in December 1, 2016. Mr. Dable served as the President of Bayer HealthCare Pharmaceuticals Inc., ...


CEO Compensation Analysis

Compensation vs. Market: Habib's total compensation ($USD4.33M) is about average for companies of similar size in the US market ($USD4.07M).

Compensation vs Earnings: Habib's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

5.9yrs

Average Tenure

57yo

Average Age

Experienced Management: XLRN's management team is seasoned and experienced (5.9 years average tenure).


Board Age and Tenure

8.6yrs

Average Tenure

61.5yo

Average Age

Experienced Board: XLRN's board of directors are considered experienced (8.6 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

SellUS$486,30028 Jun 19
Jean George
EntityIndividual
Role
Member of the Board of Directors
Director
Shares11,812
Max PriceUS$41.17
BuyUS$190,25017 Jun 19
Joseph Zakrzewski
EntityIndividual
Role
Member of the Board of Directors
Director
Shares5,000
Max PriceUS$38.05
BuyUS$30,366,85822 Jan 19
Celgene Corporation
EntityCompany
Shares706,206
Max PriceUS$43.00

Ownership Breakdown


Management Team

  • Kevin McLaughlin (63yo)

    Senior VP

    • Tenure: 8.9yrs
    • Compensation: US$1.54m
  • Tom Maniatis (76yo)

    Co-Founder

    • Tenure: 16.8yrs
    • Compensation: US$268.89k
  • Mark Ptashne

    Co-Founder and Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Sujay Kango (55yo)

    Senior VP & Chief Commercial Officer

    • Tenure: 1.7yrs
    • Compensation: US$2.37m
  • Ravi Kumar (59yo)

    Chief Scientific Officer & Senior VP

    • Tenure: 0yrs
    • Compensation: US$1.51m
  • John Quisel (48yo)

    Executive VP & Chief Business Officer

    • Tenure: 0yrs
    • Compensation: US$1.80m
  • Todd James

    Vice President of Investor Relations & Corporate Communications

    • Tenure: 0yrs
  • Habib Dable (50yo)

    CEO, President & Director

    • Tenure: 2.8yrs
    • Compensation: US$4.33m
  • Adam Veness

    VP, General Counsel & Secretary

    • Tenure: 0yrs
  • Lisa Wyman

    Vice President of Operations

    • Tenure: 0.8yrs

Board Members

  • Jean George (61yo)

    Director

    • Tenure: 14.8yrs
    • Compensation: US$283.89k
  • Richard Pops (57yo)

    Director

    • Tenure: 15.3yrs
    • Compensation: US$268.89k
  • Terry Kearney (64yo)

    Director

    • Tenure: 5.3yrs
    • Compensation: US$288.06k
  • Tom Maniatis (76yo)

    Co-Founder

    • Tenure: 16.8yrs
    • Compensation: US$268.89k
  • Bruce Spiegelman

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Mark Ptashne

    Co-Founder and Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Joe Zakrzewski (57yo)

    Director

    • Tenure: 8.6yrs
    • Compensation: US$290.97k
  • Joan Massague (66yo)

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Francois Nader (62yo)

    Chairman of The Board

    • Tenure: 4.6yrs
    • Compensation: US$303.06k
  • Habib Dable (50yo)

    CEO, President & Director

    • Tenure: 2.8yrs
    • Compensation: US$4.33m

Company Information

Acceleron Pharma Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Acceleron Pharma Inc.
  • Ticker: XLRN
  • Exchange: NasdaqGM
  • Founded: 2003
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$2.247b
  • Shares outstanding: 52.83m
  • Website: https://www.acceleronpharma.com

Number of Employees


Location

  • Acceleron Pharma Inc.
  • 128 Sidney Street
  • Cambridge
  • Massachusetts
  • 2139
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
XLRNNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDSep 2013
0A3DB (Deutsche Boerse AG)YesCommon StockDEEURSep 2013

Biography

Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its therapeutic candidate ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/22 00:13
End of Day Share Price2019/10/21 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.